Moderna's new and improved COVID vaccine produced positive trial results
By Tomi Kilgore
MRNA-1283 showed higher immunity than its Spikevax vaccine against Omicron and original COVID strains
Moderna Inc. announced Tuesday that its next-generation COVID vaccine produced better immune results in a late-stage trial than its previous vaccines, and will be a key part of its combination therapy against flu and COVID-19.
The biotechnology company (MRNA) said mRNA-1283 has met the primary endpoints of a Phase 3 trial, as it demonstrated a higher immune response against the Omicron BA.4/BA.5 and original virus strains of COVID-19, when compared with its Spikevax and mRNA-1273.222 vaccines.
"MRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market," said Chief Executive Stéphane Bancel.
Moderna's stock rose 1.1% in premarket trading, to put it on track for a fourth-straight gain.
The company said that the mRNA-1283's improved immunity response was importantly more acute in participants of the trial that were over 65-years old, which is the age population at most risk of severe illness from COVID-19.
The most common side effect of the vaccine was pain at the site of injection, while the most common adverse side effects included headaches, fatigue, muscle pain and chills.
The stock has rallied 11% year to date through Monday, while the S&P 500 has gained 9.4%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-26-24 0832ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now